Table 3.

Model-adjusted risk of mortality complemented by restricted mean survival time analysis according to type of anti–COVID-19 therapy in patients with cancer and SARS-CoV-2 infection

	Cox proportional model	Covariates
Therapy	HR (95% CI)	Sex (M/F)	Age (<65/≥65 years)	Tumor stage (advanced/nonadvanced)	RMST difference (95% CI)
	P value				P value
Antimalarials only (n = 182)	0.41 (0.26–0.66)	1.20 (0.89–1.63)	2.81 (1.90–4.17)	1.20 (0.87–1.66)	8.00 (5.50–10.52)
vs. no drug (n = 446)	P < 0.0001	P = 0.23	P < 0.0001	P = 0.27	P < 0.0001
Antivirals only (n = 16)	0.75 (0.32–1.79)	1.35 (1.00–1.89)	2.96 (1.90–4.62)	1.13 (0.78–1.63)	0.29 (−0.19–0.77)
vs. no drug (n = 446)	P = 0.52	P = 0.08	P < 0.0001	P = 0.51	P = 0.23
Tocilizumab (n = 51)	0.80 (0.37–1.74)	1.43 (1.03–2.00)	2.61 (1.74–3.92)	1.28 (0.90–1.82)	2.64 (0.90–4.38)
vs. no drug (n = 446)	P = 0.57	P = 0.03	P < 0.0001	P = 0.16	P = 0.003